1023 ECP SparingVision
BioCentury & Getty Images

Emerging Company Profile

SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease

SparingVision prepares to enter the clinic in 2H21 with a €44.5M series A tranche and new CEO

SparingVision prepares to enter the clinic in 2H21 with a €44.5M series A tranche and new CEO Stéphane Boissel.

Oct 24, 2020 | 1:53 AM GMT

SparingVision thinks its neuroprotective AAV therapy could benefit

Read the full 698 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE